Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Lancet Oncol. 2020 Mar 17;21(4):541–550. doi: 10.1016/S1470-2045(20)30023-1

Figure 1.

Figure 1.

Response to single agent nivolumab in relapsed pediatric solid tumor cohorts. Cohort B1(neuroblastoma measurable disease) and Cohort B8 (neuroblastoma non-measurable) patients are reported separtely in this figure.